AsedaSciences and Clyde Biosciences Announce Commercial Agreement to Integrate Human-Relevant Cardiotoxicity Screening

AsedaSciences and Clyde Biosciences announced a strategic sales and marketing agreement to integrate Clyde Bio’s CellOPTIQ® cardiotoxicity platform into the AsedaSciences 3RnD® platform.1

CellOPTIQ® generates high-content, human-relevant cardiomyocyte functional data measuring voltage, calcium, and contractility, supporting the CiPA in vitro Proarrhythmia Assay and reducing animal testing.1

The integration allows deployment as front-line or confirmatory assay for cardiotoxicity risk assessment within a tiered, data-driven framework.1

As part of the agreement, they will jointly expand a comparative reference library in 3RnD for benchmarking against historical compound data.1

Brad Calvin, CEO of AsedaSciences, highlighted access to one of the most predictive cardiomyocyte safety assays; Richard Henderson, CEO of Clyde Biosciences, noted enhanced decision-making in R&D.1

CellOPTIQ® is validated through collaborations with pharma companies, CiPA, HESI, and FDA.1

Sources:

1. https://www.einpresswire.com/article/886781822/asedasciences-and-clyde-biosciences-announce-commercial-agreement-to-integrate-human-relevant-cardiotoxicity-screening